Version 1
: Received: 17 August 2023 / Approved: 17 August 2023 / Online: 17 August 2023 (11:55:20 CEST)
Version 2
: Received: 16 December 2023 / Approved: 18 December 2023 / Online: 19 December 2023 (02:20:56 CET)
How to cite:
Khan, I.; Iqbal, Z.; Khan, A.; Ahmad, L.; Khan, A.; Khan, S.A.; Kazi, M. Surface Modification and Functionalization of Sorafenib-Loaded PLGA Nanoparticles for Targeting Hepatocellular and Renal Cell Carcinoma. Preprints2023, 2023081277. https://doi.org/10.20944/preprints202308.1277.v1
Khan, I.; Iqbal, Z.; Khan, A.; Ahmad, L.; Khan, A.; Khan, S.A.; Kazi, M. Surface Modification and Functionalization of Sorafenib-Loaded PLGA Nanoparticles for Targeting Hepatocellular and Renal Cell Carcinoma. Preprints 2023, 2023081277. https://doi.org/10.20944/preprints202308.1277.v1
Khan, I.; Iqbal, Z.; Khan, A.; Ahmad, L.; Khan, A.; Khan, S.A.; Kazi, M. Surface Modification and Functionalization of Sorafenib-Loaded PLGA Nanoparticles for Targeting Hepatocellular and Renal Cell Carcinoma. Preprints2023, 2023081277. https://doi.org/10.20944/preprints202308.1277.v1
APA Style
Khan, I., Iqbal, Z., Khan, A., Ahmad, L., Khan, A., Khan, S.A., & Kazi, M. (2023). Surface Modification and Functionalization of Sorafenib-Loaded PLGA Nanoparticles for Targeting Hepatocellular and Renal Cell Carcinoma. Preprints. https://doi.org/10.20944/preprints202308.1277.v1
Chicago/Turabian Style
Khan, I., Saeed Ahmad Khan and Mohsin Kazi. 2023 "Surface Modification and Functionalization of Sorafenib-Loaded PLGA Nanoparticles for Targeting Hepatocellular and Renal Cell Carcinoma" Preprints. https://doi.org/10.20944/preprints202308.1277.v1
Abstract
The aim of this study is to improve the therapeutic effectiveness of the sorafenib loaded polymeric nanoparticles, surface modified by the pluronic F-127 for the treatment of hepatocellular (HCC) and renal cell carcinomas (RCC). Poly Lactic co-glycolic acid (PLGA) was used to encapsulate sorafenib by simple modified solvent evaporation technique. The nanoparticles were prepared with different concentration of sorafenib and pluronic F-127 keeping PLGA concentration constant. There were no incompatibilities among the sorafenib, PLGA and pluronic F-127 showing that the integrity of polymer, stabilizer and drug remain the same under different conditions. The size of the coated and plain PLGA nanoparticles were ~140 ± 14.7 nm and ~ 200 ± 10.1 nm, respectively. The in-vitro release studies demonstrated that the PLGA controlled the release of sorafenib, avoiding the initial burst release. The effect of coated and plain nanoformulations was found out in squamous cell carcinoma cells. The results showed that surface modified nanoparticles treated hepatocellular and renal carcinoma in a better way as compared to plain PLGA nanoparticles and free dug by keeping the dose constant (20 mg/kg body weight).The targeted delivery of polymeric PLGA nanoparticles into squamous cell carcinoma was improved. The pharmacokinetic parameters have been improved significantly as compared to the reported nanoformulations.
Keywords
sorafenib; PLGA; Pluronic F-127; Nanosuspension; in-vitro release and in-vivo pharmacokinetics
Subject
Medicine and Pharmacology, Clinical Medicine
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
,
,
